Abstract
Summary
According to our LPI (LP Information) latest study, the global Generic Injectables market size was valued at US$ 29940 million in 2023. With growing demand in downstream market, the Generic Injectables is forecast to a readjusted size of US$ 38440 million by 2030 with a CAGR of 3.6% during review period. _x000D_
The research report highlights the growth potential of the global Generic Injectables market. Generic Injectables are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Generic Injectables. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Generic Injectables market._x000D_
Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost._x000D_
In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC._x000D_
Key Features:_x000D_
The report on Generic Injectables market reflects various aspects and provide valuable insights into the industry._x000D_
Market Size and Growth: The research report provide an overview of the current size and growth of the Generic Injectables market. It may include historical data, market segmentation by Type (e.g., Small Molecule, Large Molecule), and regional breakdowns._x000D_
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Generic Injectables market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs._x000D_
Competitive Landscape: The research report provides analysis of the competitive landscape within the Generic Injectables market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market._x000D_
Technological Developments: The research report can delve into the latest technological developments in the Generic Injectables industry. This include advancements in Generic Injectables technology, Generic Injectables new entrants, Generic Injectables new investment, and other innovations that are shaping the future of Generic Injectables._x000D_
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Generic Injectables market. It includes factors influencing customer ' purchasing decisions, preferences for Generic Injectables product._x000D_
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Generic Injectables market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Generic Injectables market. The report also evaluates the effectiveness of these policies in driving market growth._x000D_
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Generic Injectables market. _x000D_
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Generic Injectables industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments._x000D_
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Generic Injectables market._x000D_
Market Segmentation:_x000D_
Generic Injectables market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value._x000D_
Segmentation by type_x000D_
Small Molecule_x000D_
Large Molecule_x000D_
Segmentation by application_x000D_
Oncology_x000D_
Anesthesia_x000D_
Anti-Infectives_x000D_
Parenteral Nutrition_x000D_
Cardiovascular Diseases_x000D_
This report also splits the market by region:_x000D_
Americas_x000D_
United States_x000D_
Canada_x000D_
Mexico_x000D_
Brazil_x000D_
APAC_x000D_
China_x000D_
Japan_x000D_
Korea_x000D_
Southeast Asia_x000D_
India_x000D_
Australia_x000D_
Europe_x000D_
Germany_x000D_
France_x000D_
UK_x000D_
Italy_x000D_
Russia_x000D_
Middle East & Africa_x000D_
Egypt_x000D_
South Africa_x000D_
Israel_x000D_
Turkey_x000D_
GCC Countries_x000D_
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration._x000D_
Hospira (Pfizer Inc.)_x000D_
Fresenius Kabi_x000D_
Sandoz (Novartis)_x000D_
Hikma Pharmaceuticals PLC_x000D_
Dr. Reddy’s Laboratories Ltd_x000D_
Grifols_x000D_
Nichi-Iko Group (Sagent)_x000D_
Teva Pharmaceutical_x000D_
Auromedics_x000D_
Sanofi_x000D_
Gland Pharma_x000D_
Endo International PLC_x000D_
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Generic Injectables Market Size 2019-2030
2.1.2 Generic Injectables Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Generic Injectables Segment by Type
2.2.1 Small Molecule
2.2.2 Large Molecule
2.3 Generic Injectables Market Size by Type
2.3.1 Generic Injectables Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Generic Injectables Market Size Market Share by Type (2019-2024)
2.4 Generic Injectables Segment by Application
2.4.1 Oncology
2.4.2 Anesthesia
2.4.3 Anti-Infectives
2.4.4 Parenteral Nutrition
2.4.5 Cardiovascular Diseases
2.5 Generic Injectables Market Size by Application
2.5.1 Generic Injectables Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Generic Injectables Market Size Market Share by Application (2019-2024)
3 Generic Injectables Market Size by Player
3.1 Generic Injectables Market Size Market Share by Players
3.1.1 Global Generic Injectables Revenue by Players (2019-2024)
3.1.2 Global Generic Injectables Revenue Market Share by Players (2019-2024)
3.2 Global Generic Injectables Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Generic Injectables by Regions
4.1 Generic Injectables Market Size by Regions (2019-2024)
4.2 Americas Generic Injectables Market Size Growth (2019-2024)
4.3 APAC Generic Injectables Market Size Growth (2019-2024)
4.4 Europe Generic Injectables Market Size Growth (2019-2024)
4.5 Middle East & Africa Generic Injectables Market Size Growth (2019-2024)
5 Americas
5.1 Americas Generic Injectables Market Size by Country (2019-2024)
5.2 Americas Generic Injectables Market Size by Type (2019-2024)
5.3 Americas Generic Injectables Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Generic Injectables Market Size by Region (2019-2024)
6.2 APAC Generic Injectables Market Size by Type (2019-2024)
6.3 APAC Generic Injectables Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Generic Injectables by Country (2019-2024)
7.2 Europe Generic Injectables Market Size by Type (2019-2024)
7.3 Europe Generic Injectables Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Generic Injectables by Region (2019-2024)
8.2 Middle East & Africa Generic Injectables Market Size by Type (2019-2024)
8.3 Middle East & Africa Generic Injectables Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Generic Injectables Market Forecast
10.1 Global Generic Injectables Forecast by Regions (2025-2030)
10.1.1 Global Generic Injectables Forecast by Regions (2025-2030)
10.1.2 Americas Generic Injectables Forecast
10.1.3 APAC Generic Injectables Forecast
10.1.4 Europe Generic Injectables Forecast
10.1.5 Middle East & Africa Generic Injectables Forecast
10.2 Americas Generic Injectables Forecast by Country (2025-2030)
10.2.1 United States Generic Injectables Market Forecast
10.2.2 Canada Generic Injectables Market Forecast
10.2.3 Mexico Generic Injectables Market Forecast
10.2.4 Brazil Generic Injectables Market Forecast
10.3 APAC Generic Injectables Forecast by Region (2025-2030)
10.3.1 China Generic Injectables Market Forecast
10.3.2 Japan Generic Injectables Market Forecast
10.3.3 Korea Generic Injectables Market Forecast
10.3.4 Southeast Asia Generic Injectables Market Forecast
10.3.5 India Generic Injectables Market Forecast
10.3.6 Australia Generic Injectables Market Forecast
10.4 Europe Generic Injectables Forecast by Country (2025-2030)
10.4.1 Germany Generic Injectables Market Forecast
10.4.2 France Generic Injectables Market Forecast
10.4.3 UK Generic Injectables Market Forecast
10.4.4 Italy Generic Injectables Market Forecast
10.4.5 Russia Generic Injectables Market Forecast
10.5 Middle East & Africa Generic Injectables Forecast by Region (2025-2030)
10.5.1 Egypt Generic Injectables Market Forecast
10.5.2 South Africa Generic Injectables Market Forecast
10.5.3 Israel Generic Injectables Market Forecast
10.5.4 Turkey Generic Injectables Market Forecast
10.5.5 GCC Countries Generic Injectables Market Forecast
10.6 Global Generic Injectables Forecast by Type (2025-2030)
10.7 Global Generic Injectables Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Hospira (Pfizer Inc.)
11.1.1 Hospira (Pfizer Inc.) Company Information
11.1.2 Hospira (Pfizer Inc.) Generic Injectables Product Offered
11.1.3 Hospira (Pfizer Inc.) Generic Injectables Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Hospira (Pfizer Inc.) Main Business Overview
11.1.5 Hospira (Pfizer Inc.) Latest Developments
11.2 Fresenius Kabi
11.2.1 Fresenius Kabi Company Information
11.2.2 Fresenius Kabi Generic Injectables Product Offered
11.2.3 Fresenius Kabi Generic Injectables Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Fresenius Kabi Main Business Overview
11.2.5 Fresenius Kabi Latest Developments
11.3 Sandoz (Novartis)
11.3.1 Sandoz (Novartis) Company Information
11.3.2 Sandoz (Novartis) Generic Injectables Product Offered
11.3.3 Sandoz (Novartis) Generic Injectables Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Sandoz (Novartis) Main Business Overview
11.3.5 Sandoz (Novartis) Latest Developments
11.4 Hikma Pharmaceuticals PLC
11.4.1 Hikma Pharmaceuticals PLC Company Information
11.4.2 Hikma Pharmaceuticals PLC Generic Injectables Product Offered
11.4.3 Hikma Pharmaceuticals PLC Generic Injectables Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Hikma Pharmaceuticals PLC Main Business Overview
11.4.5 Hikma Pharmaceuticals PLC Latest Developments
11.5 Dr. Reddy’s Laboratories Ltd
11.5.1 Dr. Reddy’s Laboratories Ltd Company Information
11.5.2 Dr. Reddy’s Laboratories Ltd Generic Injectables Product Offered
11.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Dr. Reddy’s Laboratories Ltd Main Business Overview
11.5.5 Dr. Reddy’s Laboratories Ltd Latest Developments
11.6 Grifols
11.6.1 Grifols Company Information
11.6.2 Grifols Generic Injectables Product Offered
11.6.3 Grifols Generic Injectables Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Grifols Main Business Overview
11.6.5 Grifols Latest Developments
11.7 Nichi-Iko Group (Sagent)
11.7.1 Nichi-Iko Group (Sagent) Company Information
11.7.2 Nichi-Iko Group (Sagent) Generic Injectables Product Offered
11.7.3 Nichi-Iko Group (Sagent) Generic Injectables Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Nichi-Iko Group (Sagent) Main Business Overview
11.7.5 Nichi-Iko Group (Sagent) Latest Developments
11.8 Teva Pharmaceutical
11.8.1 Teva Pharmaceutical Company Information
11.8.2 Teva Pharmaceutical Generic Injectables Product Offered
11.8.3 Teva Pharmaceutical Generic Injectables Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Teva Pharmaceutical Main Business Overview
11.8.5 Teva Pharmaceutical Latest Developments
11.9 Auromedics
11.9.1 Auromedics Company Information
11.9.2 Auromedics Generic Injectables Product Offered
11.9.3 Auromedics Generic Injectables Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Auromedics Main Business Overview
11.9.5 Auromedics Latest Developments
11.10 Sanofi
11.10.1 Sanofi Company Information
11.10.2 Sanofi Generic Injectables Product Offered
11.10.3 Sanofi Generic Injectables Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Sanofi Main Business Overview
11.10.5 Sanofi Latest Developments
11.11 Gland Pharma
11.11.1 Gland Pharma Company Information
11.11.2 Gland Pharma Generic Injectables Product Offered
11.11.3 Gland Pharma Generic Injectables Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Gland Pharma Main Business Overview
11.11.5 Gland Pharma Latest Developments
11.12 Endo International PLC
11.12.1 Endo International PLC Company Information
11.12.2 Endo International PLC Generic Injectables Product Offered
11.12.3 Endo International PLC Generic Injectables Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Endo International PLC Main Business Overview
11.12.5 Endo International PLC Latest Developments
12 Research Findings and Conclusion